Brainstorm Cell Therapeutics heads into the weekend with a sharp dislocation in its lending market — cost to borrow has more than doubled in a week — even as short sellers hold a position that is tiny relative to the float.
The most striking data point right now is in the borrow market, not the short book. Cost to borrow has climbed to 10.37%, up 146% week-on-week and nearly double where it stood a month ago. As recently as May 7, CTB was sitting around 4.2%. The move to double digits is notable for a stock of this size, and it comes precisely as the company filed its Q1 10-Q on May 15 and reported EPS of -$0.19 — a beat of $0.17 against the consensus estimate. That result landed on the same day the CTB spike registered its highest reading of the tracked period. Whether the earnings beat triggered renewed short-covering demand, or whether the spike reflects pre-release positioning, the borrow market tightened sharply either way.
Short interest itself tells a much quieter story. SI amounts to just 0.53% of free float — a level that makes BCLI genuinely lightly shorted by any standard. More telling is the trend: shorts have been covering for weeks. From a local peak above 0.90% of float in early April, estimated short interest has fallen roughly 40% through mid-May. The ORTEX short score of 49 is broadly neutral, consistent with a market that is neither building conviction to the downside nor scrambling to exit. The days-to-cover reading of 2.37 days confirms there is no structural squeeze dynamic at work here.
Availability in the lending pool has tightened in parallel with the CTB move, consistent with the borrow cost signal. Availability is running at approximately 43% of outstanding short interest — tighter than the mid-April range of 40-52%, though well above the 52-week low implied by the 77% utilization peak recorded earlier in the year. The combination of a falling short base and rising borrow costs is an unusual one: it suggests demand for borrows is meeting a shrinking supply pool, even as the aggregate short position is being reduced.
On the fundamental side, the Q1 beat is the most recent concrete catalyst. BCLI reported full-year 2025 net loss of $10.3 million, down from $11.6 million the prior year — a modest narrowing. The company received $3 million in equity funding across two tranches earlier this year. None of these events individually shifts the investment thesis materially, but the EPS beat, combined with the borrow cost spike, gives the week an active feel that the headline price action — down 20% over the past month and 66% over the week on very thin liquidity — does not fully explain. Historical earnings reactions have been mixed: the last four prints produced 1-day moves ranging from -1.4% to +9.2%, with no consistent directional pattern. The Q1 2026 result is already in market hands; the next formal event is the formally scheduled Q1 reporting on May 20.
The key thing to watch is whether the CTB spike resolves quickly — a reversion to the 4-5% range would suggest the move was technical and short-lived — or whether the tighter availability persists, which would indicate genuine incremental demand for borrows at this new, higher cost level.
See the live data behind this article on ORTEX.
Open BCLI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
